Avicenna publishes provisional executive summary on “The role of Artificial Intelligence within in silico medicine” and comments on the European Commission’s White Paper on AI
On 12 June, the Avicenna Alliance has submitted Members’ feedback through the European Commission’s public consultation on its White Paper on artificial intelligence and released a new publication on the role of Artificial Intelligence within in silico medicine.
Following the publication of a new policy package, including the European strategy for data and White Paper on artificial intelligence, the European Commission launched a consultation period to gather views from stakeholders on its White Paper on artificial intelligence until the 14 June.
Members of the Avicenna Alliance were eager to provide feedback to this important publication and therefore started working on an Avicenna Alliance white paper on ‘’the role of artificial intelligence within in silico medicine”. Given the great interest shown by the members of the Alliance and the time necessary to respond to the European Commission's public consultation on AI, it was decided to produce a provisional executive summary on “The role of Artificial Intelligence within in silico medicine “ as an introduction to the white paper to be published later in 2020 to provide feedback to the European Commission.
The Avicenna Alliance is therefore proud to share with you the common feedback provided to the European Commission’s survey and more importantly the provisional executive summary on “The role of Artificial Intelligence within in silico medicine”!
Please also consult the “Avicenna Alliance Position Paper - AI and Big Data effective readiness” which applies also to the White Paper on Artificial Intelligence and constitutes the starting point for a much-needed discussion on how the policy framework governing AI & Data in the health care sector.
We would like to thank all Avicenna Members for their contributions which enabled the Alliance to provide the EU policy makers with this common response endorsed by 22 Members from medtech, pharmaceutical, software and life science industries and scientific community from academia.